Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 216

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 216
---
 offset by the interest earned on marketable securities held in Trust Account of $2,836,864.

<div align='center'>125</div>

Liquidity and Going Concern

On October 8, 2021,
we consummated the Initial Public Offering of 17,500,000 units (“Units”), at a price of $10.00 per Unit, which included the
partial exercise by the underwriter of its over-allotment option in the amount of 2,000,000 Units, generating gross proceeds of $175,000,000.
Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 885,000 units (the “Private Placement
Units”) to the Sponsor, Cantor Fitzgerald & Co. (“Cantor”) and Cohen & Company Capital Markets, a division
of J.V.B. Financial Group, LLC (“CCM”), at a price of $10.00 per Private Placement Unit, generating gross proceeds of $8,850,000.

Following the Initial Public
Offering, the partial exercise of the over-allotment option and the sale of the Private Placement Units, a total of $178,500,000 was
placed in the Trust Account ($10.20 per Unit). We incurred $12,729,318 in transaction costs, including $2,635,000 of underwriting fees,
$9,150,000 of deferred underwriting fees and $944,318 of other offering costs.

As of December 31, 2023,
we had $96,873 in our operating bank accounts, $8,436,311 in money market funds held in Trust Account to be used for a business combination
or to repurchase or redeem our Public Shares in connection therewith and a working capital deficit of $5,049,122.

For the year ended December
31, 2023, there was $1,523,604 of cash used in operating activities.

For the year ended December
31, 2022, there was $1,092,247 of cash used in operating activities.

We used substantially all
of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes payable),
to complete our Business Combination, including the payment of transaction costs.

In order to finance transaction
costs in connection with a business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors
may, but are not obligated to, loan us funds